Mereo Biopharma Share Price (MPH)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Mereo Biopharma Group Plc LSE:MPH London Ordinary Share GB00BZ4G2K23 ORD GBP0.003 (REG S)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 26.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
26.00 27.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -41.12 -39.00 73
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 26.50 GBX
Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Motif Bio (MTFB), Bermele (BERM)

Mereo Biopharma (MPH) Latest News

Mereo Biopharma News

Date Time Source Headline
18/12/202022:17ALNCUK TRADING UPDATE SUMMARY: Yamana Completes Agua Rica Project
18/12/202007:00UKREGAIM Cancellation - Mereo Biopharma Group plc
15/12/202018:22UKREGMereo BioPharma Group plc AIM Delisting
30/11/202007:00RNSNONMereo BioPharma Group plc Key Dates for AIM Delisting
23/11/202016:22ALNCUK EXECUTIVE CHANGE SUMMARY: Gulf Marine Services Suspends Exiting CEO
23/11/202012:00RNSNONMereo BioPharma Group plc Mereo appoints Suba Krishnan
16/11/202012:00RNSNONMereo BioPharma Group plc Virtual R&D Day
11/11/202020:17ALNCUK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus
11/11/202007:00UKREGMereo BioPharma Group plc Cancellation of AIM admission
10/11/202012:00RNSNONMereo BioPharma Group plc Stifel 2020 Virtual Healthcare Conference
More Mereo Biopharma News
Mereo Biopharma Investors    Mereo Biopharma Takeover Rumours

Mereo Biopharma (MPH) Discussions and Chat

Mereo Biopharma Forums and Chat

Date Time Title Posts
18/2/202121:29MPH the pharma nobody knows about ***Ј3 ->>>>Ј8***700
20/5/202016:27Mereo Biopharma-
26/1/200911:56Marchpole: A Global Future: The Time is Now4,780
06/7/200815:45WARNING! For double bottom speculators only please.30
22/2/200815:24Marchpole hits the deck!9

Add a New Thread

Mereo Biopharma (MPH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Mereo Biopharma trades in real-time

Mereo Biopharma (MPH) Top Chat Posts

DateSubject
01/8/2021
09:20		Mereo Biopharma Daily Update: Mereo Biopharma Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MPH. The last closing price for Mereo Biopharma was 26.50p.
Mereo Biopharma Group Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 60p while the 1 year low share price is currently 26p.
There are currently 273,652,487 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Mereo Biopharma Group Plc is £72,517,909.06.
Read Full Thread
Reply
25/11/2020
12:15		boggy: Hi I have received a letter from my broker (EQi) saying they will automatically convert my shares held in an ISA with them to ADR's on 30 November. However they can't stay in the ISA so new shares will be put into my trading account. Not sure whether to sell now or just forego the ISA allowance and just sit on them in the hope they increase dramatically....what are others views? No difference in price now between AIM and Nasdaq
Read Full Thread
Follow
Reply
11/11/2020
09:28		donmac101: Free money as current price on nasdaq is over 36p.
Read Full Thread
Follow
Reply
28/9/2020
13:58		avsome1968: ondon and Redwood City, Calif., September 28, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces the appointments of two new members to the Company's Board of Directors. Dr. Brian Schwartz, former Chief Medical Officer of Arqule, Inc. and Dr. Jeremy Bender, former Vice President of Corporate Development at Gilead Sciences, Inc. and recently appointed Chief Executive Officer of Day One Biopharmaceuticals, Inc., will join Mereo's Board of Directors. Drs. Schwartz and Bender bring significant oncology drug development and corporate development experience to Mereo. In addition, in order to maintain the maximum number of board members at nine, Paul Blackburn will be leaving Mereo's Board of Directors after a five-year tenure as a Non-Executive Director. The changes to the Mereo Board will be made with effect from October 1, 2020. "We are very pleased to strengthen our board of directors at this important stage in Mereo's evolution," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "Brian and Jeremy are industry veterans with deep experience in clinical and corporate development specifically within oncology and rare diseases. Their collective skill sets will be an asset to Mereo as we prepare to advance etigilimab, our anti-TIGIT antibody, into a Phase 1b/2 combination study in the fourth quarter this year and continue to execute on our broader rare disease pipeline strategy." Peter Fellner, Chairman of the Board of Directors of Mereo, said: "Mereo is entering an exciting new chapter and we are delighted to welcome Brian and Jeremy to our distinguished Board of Directors. On behalf of the Board, we would also like to thank Paul for his contributions over the past five years especially for his leadership as Chairman of the Audit and Risk Committee. He leaves the Board with the Company well financed and in a strong position to execute on our strategy. We wish him the best in his future endeavours."
Read Full Thread
Follow
Reply
06/6/2020
22:52		master rsi: Confirmation of Acacia Research bought the rest of the MPH stake from Woodford fund. "Market stock Mereo Biopharma (MPHM) also feature, according to the report." Woodford fund tumbles 20% on cut-price stocks sale Woodford Equity Income hit by £114m loss as stakes in up to 19 of the failed fund's biotech stocks are sold to US investor Acacia Research. By Daniel Grote - 05 Jun, 2020 The Woodford Equity Income fund has slumped by 20% after a number of the failed fund’s biotech stocks were sold to US investor Acacia Research (ACTG.O) in a cut-price deal. Fund administrator Link Fund Solutions has sold up to 19 of the fund’s biotech stocks representing half of its assets to Acacia in a £224m deal. The deal for the assets, struck at a price well below the level at which the stocks were being valued by the fund, has wiped £114m off its net asset value, which has dropped from £558m to £444m. The slump has taken investors’ losses on the fund since it was suspended one year ago to 27%. Ryan Hughes, head of active portfolios at AJ Bell, said the price of the deal would be met with ‘huge frustation’ from investors trapped in the fund. ‘This highlights the very real problem of being a forced seller with all potential purchasers knowing that... Link were in no position to try and push the price higher,’ he said. Link said in a letter to investors the deal would pave the way for further payments to investors in the fund, but warned some aspects of the deal could take up to six months to complete. ‘We are currently unable to confirm the exact dates and amounts in respect of these further capital distributions but we will write to you with an update no later than 29 July,’ it said. So far investors in the fund, which stood at £3.7bn at the time of its suspension, have received payments of £2.3bn, distributed in January and March this year. Shares in US-listed Acacia have soared 27% over the last two days after Sky News reported earlier this week the group was closing in on a deal to acquire Woodford’s assets. According to Sky News, the deal includes Woodford’s stake in unquoted gene sequencing company Oxford Nanopore and drug developer Immunocore. US-listed Therevance Biopharma (TBPH.O) and Alternative Investment Market stock Mereo Biopharma (MPHM) also feature, according to the report. Link did not disclose the names of the stocks included in the deal. ‘The shares are in up to 19 public and private life sciences companies,’ it said. ‘Link Fund Solutions cannot comment on the particular companies involved.’ Link is also understood to have considered a deal for a smaller number of the fund’s assets from Neil Woodford, the sacked former manager of the fund, who had been approached by a number of institutional and family office investors. That bid, understood to have included offers for the fund’s stakes in Oxford Nanopore and Immunocore, was ultimately rejected in favour of Acacia’s. Agreement on the sale follows the reported collapse of a £550m bid to buy the fund’s biotech start-ups from life sciences investor WG Partners earlier this year. Woodford’s former investment trust, Schroder UK Public Private (SUPP), holds a number of the same stocks as the failed fund and said last month the sell-off by Woodford Equity Income would ‘continue to cause disruption to a number of investee companies’. The Acacia deal will not necessarily lead to markdowns in any of the trust’s shared assets, however. Link, which is also alternative investment fund manager to the trust, has said that the valuation of stocks by the fund could differ to those employed by the trust given the fund’s wind-up. Shares in Schroder UK Public Private were up 2% at 26.2p this morning. Separately, East Midlands law firm Nelsons, which has been considering a claim against Hargreaves Lansdown over its promotion of Woodford Equity Income, has said it is now exploring a case against Link. Nelsons partner Cathryn Selby said the firm was focusing on Link’s approval of Woodford’s listing of some of his unquoted companies on Guernsey’s stock exchange to avoid breaching limits on how many of these companies funds are allowed to hold. Citywire revealed Woodford’s Guernsey move last year, two months before the fund’s suspension. ‘We are looking at whether such decisions were indeed in the best interests of all investors, or whether it could be said that investors were let down by Link Fund Solutions’ apparent failure to address the substantive issue of the increasing illiquidity of the fund at a much earlier stage,’ she said.
Read Full Thread
Follow
Reply
04/6/2020
23:34		yasx: On the 25th of May, with the price at 19p, I set out my exegesis of this stock, reproduced hereto... yasX 25 May '20 - 20:01 - 539 of 654 Edit 0 6 0 It appears to me that some are perplexed by what MPH is all about. Allow me to elucidate by providing a brief precis of both the risks and potential reward here... In essence, this is not a get rich overnight share, although I opine it has been heavily sold down and there may well be a sharp rebound. But, I am certainly neither banking on nor hoping for that (indeed, it would suit me if it were to continue to decline since I would be able to accumulate more going forward at lower prices). Be that as it may, there are in my view various reasons as to why it has been sold down, as follows: a) Link/Invesco disposing of their shares. At the time of writing they hold 15.2% and 12.9% respectively, and I think there is every reason to assume they will continue to offload - this will serve to suppress the price of the shares unless... b) unless Acacia (or another outfit) take out the aforementioned overhang. It has been rumoured in recent months that Starboard have given Acacia some $400 million to make a few acquisitions and that one of the targets has been the remnants of Woodford's previous holdings (which includes MPH). There has been a vague rumour in the press that Woodford himself may well be interested. Irrespective of who might take up the slack, this would be a positive development for the shares since it would remove the overhang that is suppressing the shares. c)The Co. has a very high burn rate - that is not a surprise since outfits of this type do incur considerable expenditure to prove up the potential drugs. There is the prospect of further funding.financing this year, but this might not just be in the form of equity issuance but different financing arrangements are also likely. The Co. has recently entered into two financing deals earlier this year and undoubtedly there will be more either in the short term or later this year. The nature of those deals will impact on the shares, favourably or otherwise (I suspect favourably since given the potential of the drugs any equity raising will surely not be contemplated below the rpice paid by the recent US institutional investor and partnership arrangements will be most welcome - Navicixizumab was earlier this year licensed to Oncologie for approx $6M upfront and up to $300M in future milestone payments/royalties). d) Targeting further drug acquisitions which at this stage I would prefer they left alone - they have enough to be getting on with and it only needs one strike for this to go into orbit. The key offering is Setrusumab for osteogenesis which has thus far demonstrated positive output data notiwthstanding a failure to meet the primary endpoint (I know that sounds rather silly, but not so when one considers that subsequent to the Phase 2b they are now embarking on a Phase 3 study pursuant to guidance from the FDA.This will take at least a year so nothing to get excited about regarding this study in the very near term. Make no mistake, this is a binary bet with no certainty of success, but, if they pull it off.... e) They also have Alvelestat, with potential for a rare respiratory disease , at Phase 2 stage - we should get more on this at some point this year. All of this consumes cash, as explained above. The exact cash position is not known since the last stated amount will now be dramatically different, although I expect they probably do not have a substantial amount and will likely as pointed out earlier require further funds this year, the form of which is not yet known (at least not to me). I think they have demonstrated a good track record of entering into partnerships and the ability to raise cash via equity raisings (I would not like to see placing at or around this level since I think this undervalues the potential of the product portfolio. One factor I need to consider in more detail is the track record of the Board - I personally have not invested in any outfit they have previously been involved in, and aside from having reviewed their profiles have nothing further to say on that aspect for now. Incidentally, I was not overly impressed with the Proactive interview with the CEO (she did not strike me as being very capable, but then, perhaps that was just my assessment of it). In summary, do not expect drug success overnight. Do bear in mind that these offerings need expenditure, and currently they are not fully funded to commercialisation. But, the shares in my view do not reflect the potential of the pipeline and I think once this overhang clears, and with an announcement or two relating to further financing arrangements, this could well double or treble this year before any potentially epochal development relating to any of the study outcomes (and particularly Setrusumab emerges. That is how I intend to play this - I will sell some when the shares on the way up (for so I assume) and hit my assumed double, treble or whatever price point ahead, and then I intend to run the rest as free carry and see if they have a successful outcome on any of the offerings. IN short, I think on potential these will race higher at some point, I will then sell sufficient amounts to preserve capital allowing the rest to run contingent upon study outcomes. In this way I suspect I will have a free carry that could potentially be a 20 bagger plus from these levels. I welcome counter bearish views, since these are far more preferable than bulls merely echoing the same. I like to critically assess any share I hold and well constructed bearish views are certainly invited (numpty Stig need not bother). Incidentally, I rarely change my view based on what others suggest but it is never a bad thing to review the merits of an investment based on any critical analysis. As it happens, it has played out exactly as I had anticipated - only much quicker. I have taken most of them off the table since the rise was very sharp in the near term - but, the long term thesis remains unchanged and is contingent upon the outcome of the trials and further partnership/financing deals. The potential remains huge..
Read Full Thread
Follow
Reply
03/6/2020
14:08		stopstopgo: By following the correct MREO/MPH price conversion procedure outlined in post 451. Yesterday's VWAP for MREO was $1.90 equivalent to 30p for a MPH share. (There had been a high of $2.33. The normal hours closing price was $1.99.) The pre-opening price at 2pm BST seemed to be about $1.75, equivalent to 27.7p. The UK order book was showing 23-24p bid-offer price.
Read Full Thread
Follow
Reply
25/5/2020
20:01		yasx: It appears to me that some are perplexed by what MPH is all about. Allow me to elucidate by providing a brief precis of both the risks and potential reward here... In essence, this is not a get rich overnight share, although I opine it has been heavily sold down and there may well be a sharp rebound. But, I am certainly neither banking on nor hoping for that (indeed, it would suit me if it were to continue to decline since I would be able to accumulate more going forward at lower prices). Be that as it may, there are in my view various reasons as to why it has been sold down, as follows: a) Link/Invesco disposing of their shares. At the time of writing they hold 15.2% and 12.9% respectively, and I think there is every reason to assume they will continue to offload - this will serve to suppress the price of the shares unless... b) unless Acacia (or another outfit) take out the aforementioned overhang. It has been rumoured in recent months that Starboard have given Acacia some $400 million to make a few acquisitions and that one of the targets has been the remnants of Woodford's previous holdings (which includes MPH). There has been a vague rumour in the press that Woodford himself may well be interested. Irrespective of who might take up the slack, this would be a positive development for the shares since it would remove the overhang that is suppressing the shares. c)The Co. has a very high burn rate - that is not a surprise since outfits of this type do incur considerable expenditure to prove up the potential drugs. There is the prospect of further funding.financing this year, but this might not just be in the form of equity issuance but different financing arrangements are also likely. The Co. has recently entered into two financing deals earlier this year and undoubtedly there will be more either in the short term or later this year. The nature of those deals will impact on the shares, favourably or otherwise (I suspect favourably since given the potential of the drugs any equity raising will surely not be contemplated below the rpice paid by the recent US institutional investor and partnership arrangements will be most welcome - Navicixizumab was earlier this year licensed to Oncologie for approx $6M upfront and up to $300M in future milestone payments/royalties). d) Targeting further drug acquisitions which at this stage I would prefer they left alone - they have enough to be getting on with and it only needs one strike for this to go into orbit. The key offering is Setrusumab for osteogenesis which has thus far demonstrated positive output data notiwthstanding a failure to meet the primary endpoint (I know that sounds rather silly, but not so when one considers that subsequent to the Phase 2b they are now embarking on a Phase 3 study pursuant to guidance from the FDA.This will take at least a year so nothing to get excited about regarding this study in the very near term. Make no mistake, this is a binary bet with no certainty of success, but, if they pull it off.... e) They also have Alvelestat, with potential for a rare respiratory disease , at Phase 2 stage - we should get more on this at some point this year. All of this consumes cash, as explained above. The exact cash position is not known since the last stated amount will now be dramatically different, although I expect they probably do not have a substantial amount and will likely as pointed out earlier require further funds this year, the form of which is not yet known (at least not to me). I think they have demonstrated a good track record of entering into partnerships and the ability to raise cash via equity raisings (I would not like to see placing at or around this level since I think this undervalues the potential of the product portfolio. One factor I need to consider in more detail is the track record of the Board - I personally have not invested in any outfit they have previously been involved in, and aside from having reviewed their profiles have nothing further to say on that aspect for now. Incidentally, I was not overly impressed with the Proactive interview with the CEO (she did not strike me as being very capable, but then, perhaps that was just my assessment of it). In summary, do not expect drug success overnight. Do bear in mind that these offerings need expenditure, and currently they are not fully funded to commercialisation. But, the shares in my view do not reflect the potential of the pipeline and I think once this overhang clears, and with an announcement or two relating to further financing arrangements, this could well double or treble this year before any potentially epochal development relating to any of the study outcomes (and particularly Setrusumab emerges. That is how I intend to play this - I will sell some when the shares on the way up (for so I assume) and hit my assumed double, treble or whatever price point ahead, and then I intend to run the rest as free carry and see if they have a successful outcome on any of the offerings. IN short, I think on potential these will race higher at some point, I will then sell sufficient amounts to preserve capital allowing the rest to run contingent upon study outcomes. In this way I suspect I will have a free carry that could potentially be a 20 bagger plus from these levels. I welcome counter bearish views, since these are far more preferable than bulls merely echoing the same. I like to critically assess any share I hold and well constructed bearish views are certainly invited (numpty Stig need not bother). Incidentally, I rarely change my view based on what others suggest but it is never a bad thing to review the merits of an investment based on any critical analysis.
Read Full Thread
Follow
Reply
02/5/2020
18:34		stopstopgo: It would be best if posters on this board do not confuse ticker MPH and ticker MREO. MPH is for ordinary shares of the company bought/sold in GB pence. MREO is for American Depository Shares bought sold in USD with each ADS representing 5 ordinary shares in MPH. To work out the cost in pence for one MPH share if you know the price in dollars for one MREO ADS, you do the following. 1) Use the GBP:USD exchange rate to work out the cost of the MREO in pence. 2) Divide by 5. So on May 1st, the volume weighted average price was almost exactly $1.20 (which was pretty much the last trade price). The GBP:USD rate was 1.25. So the MREO price expressed in pence was ----- 1.20/1.25 = 0.96 pounds or 96p. and the cost of one of the shares in the 5 shares comprising the ADS was ----- 96/5 = 19.2 pence. The share price for MPH on that day 20-22 bid/offer. You would have paid more in the UK for your MPH shares than if you'd bought them through the American ADS. The number of shares traded vis MREO is far far larger that those traded via MPH. The US is the major marketplace. In the UK the market makers consistently take us for a ride. There was an RNS on 24th April 2019 explaining the relationship between MREO and MPH shares.
Read Full Thread
Follow
Reply
11/4/2020
10:34		showmethemoneyhoney01: I wonder if there Alpha 1 lung disease MPH 966 could have any positive effects on treating lung disease caused by Covid 19. Extract from website below:- Clinical Status We have commenced a Phase 2, 12-week randomized, placebo-controlled, trial evaluating two doses of MPH-966 versus placebo that is expected to enroll approximately 165 patients with the PiZZ or NULL genetic mutations. The primary endpoint of the study is the change from baseline of desmosine/isodesmosine which are biomarkers of neutrophil elastase activity. Desmosine has been shown to correlate with deterioration of lung tissue as determined by CT scans in previous studies in AATD patients. Mereo expects to report top line data in mid-2020 and if the results are positive, will seek regulatory advice on the design of a pivotal trial. A total of 12 clinical studies have been completed to date in over 1,100 patients in a range of lung diseases demonstrating safety and good tolerability. Would appreciate anyone's thoughts on this. NY Boy, could you run this past your industry contacts? I do hold some but with several projects ongoing, funding sorted, the market cap has struck me as low, even a few months ago when the share price rallied a bit.
Read Full Thread
Follow
Reply
11/4/2020
10:11		showmethemoneyhoney01: Interesting article from Jan 2020 on institutions owning MPH. Small extract below Https://simplywall.st/news/could-mereo-biopharma-group-plcs-lonmph-investor-composition-influence-the-stock-price/ What Does The Institutional Ownership Tell Us About Mereo BioPharma Group? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Mereo BioPharma Group already has institutions on the share registry. Indeed, they own 60% of the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Mereo BioPharma Group, (below). Of course, keep in mind that there are other factors to consider, too.
Read Full Thread
Follow
Reply
Mereo Biopharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
MPH
Mereo Biop..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210801 18:26:46